Intellia Therapeutics, Inc.

NTLA

Precision medicineBiotech & pharmaceuticals

$13.07vs prev close▲+0.47(+3.73%)

$7.9552W Range$28.25

25% from low

+1.01 (+8.37%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

7 buys

Consecutive buys

1M net buy

+$22.1M

≈ +1.8M shares

Portfolio Weight

1.05%

1M -0.12%p

Holding ETFs

2 ETFs

ARKG · ARKK

Price Effect (Buy)

Shares increased, but price decline reduced portfolio weight.

Shares +14.5% · Market value +15.1% · Weight -0.12%p

Trade Intensity

Consecutive buys 7

Basis: 0 sells · 7 buys in 1M · Multi-ETF simultaneous buy · weight -0.12%p decrease

Trade Log7-day BUY streak

Date	Action	ETF	Shares	Close	Est. total
26.10.09	BUY	ARKG	48,171	$13.07	$629.6K
26.10.06	BUY	ARKG · ARKK	71,604	$12.37	$885.7K
26.10.05	BUY	ARKG · ARKK	96,308	$12.75	$1.2M
26.10.02	BUY	ARKG · ARKK	511,697	$12.26	$6.3M
26.10.01	BUY	ARKG · ARKK	410,911	$12.12	$5.0M
26.09.30	BUY	ARKG · ARKK	466,956	$12.06	$5.6M
26.09.29	BUY	ARKG · ARKK	205,192	$12.03	$2.5M
26.09.11	BUY	ARKG · ARKK	114,989	$11.74	$1.3M
26.09.10	BUY	ARKG · ARKK	89,284	$11.93	$1.1M
26.09.09	BUY	ARKG · ARKK	204,206	$12.21	$2.5M
26.09.08	BUY	ARKG · ARKK	97,626	$12.74	$1.2M
26.09.04	BUY	ARKG · ARKK	31,186	$12.74	$397.3K
26.09.03	BUY	ARKG	39,548	$12.68	$501.5K
26.09.02	BUY	ARKG	96,201	$12.76	$1.2M
26.09.01	BUY	ARKG	66,186	$12.69	$839.6K

10.09BUY

48,171

ARKGClose$13.07Est. total$629.6K

10.06BUY

71,604

ARKG · ARKKClose$12.37Est. total$885.7K

10.05BUY

96,308

ARKG · ARKKClose$12.75Est. total$1.2M

10.02BUY

511,697

ARKG · ARKKClose$12.26Est. total$6.3M

10.01BUY

410,911

ARKG · ARKKClose$12.12Est. total$5.0M

09.30BUY

466,956

ARKG · ARKKClose$12.06Est. total$5.6M

09.29BUY

205,192

ARKG · ARKKClose$12.03Est. total$2.5M

09.11BUY

114,989

ARKG · ARKKClose$11.74Est. total$1.3M

09.10BUY

89,284

ARKG · ARKKClose$11.93Est. total$1.1M

09.09BUY

204,206

ARKG · ARKKClose$12.21Est. total$2.5M

09.08BUY

97,626

ARKG · ARKKClose$12.74Est. total$1.2M

09.04BUY

31,186

ARKG · ARKKClose$12.74Est. total$397.3K

09.03BUY

39,548

ARKGClose$12.68Est. total$501.5K

09.02BUY

96,201

ARKGClose$12.76Est. total$1.2M

09.01BUY

66,186

ARKGClose$12.69Est. total$839.6K

1 / 15

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

2 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

14,277,512

Portfolio Weight

1.05%

in ETF 1.62%

Est. Value

$182M

30D Net

+$28M

Ray DalioBridgewater Associates

New Buy

223,166

Portfolio Weight

0.01%

Est. Value

$2M

Change

New position

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Analyst Targets

avg.

$23.11

vs Current ▲ +76.8% upside

Current$13.07

Low ~ High$8.00 ~ $61.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Barclays

Underweight

$8.00

-38.79%

—

Upgrade

2026-10-06

Citizens

Market Outperform

$30.00

+129.53%

—

Maintain

2026-09-09

Wedbush

Neutral

$13.00

-0.54%

—

Maintain

2026-09-09

HC Wainwright & Co.

Buy

$25.00

+91.28%

—

Maintain

2026-09-09

Citizens

Market Outperform

$30.00

+129.53%

—

Maintain

2026-08-25

1 / 4

Avg Target

$23.11

vs Current ▲ +76.8% upside

Buy

20 analysts

Strong Buy 1Buy 9Hold 6Sell 2Strong Sell 2

Low $8.00

Current $13.07

High $61.00

Firm	Position	Target	Upside	Close	Action	Date
Barclays	Underweight	$8.00	-38.79%	—	Upgrade	26.10.06
Citizens	Market Outperform	$30.00	+129.53%	—	Maintain	26.09.09
Wedbush	Neutral	$13.00	-0.54%	—	Maintain	26.09.09
HC Wainwright & Co.	Buy	$25.00	+91.28%	—	Maintain	26.09.09
Citizens	Market Outperform	$30.00	+129.53%	—	Maintain	26.08.25

1 / 4

Price Information

Previous Close$12.60

Open$12.39

Day Range$11.94 - $13.27

52-Week Range$7.95 - $28.25

1-Year Change-44.99%

Trading Volume

Volume8,154,715

Avg Volume (3mo)4,291,667

Valuation

Market Cap1.8B

Book Value$5.20

Shares Outstanding140,126,693

Financials

Revenue (TTM)59.5M

Net Income-399,975,008

EPS$-3.35

EBITDA-414,400,000

Profitability

P/E Ratio-

P/B Ratio2.51

Return on Equity (ROE)-55.44%

Return on Assets (ROA)-30.14%

Profit Margin0.00%

EV/EBITDA-3.54

Beta1.80

Dividend

Dividend Rate-

Dividend Yield0.00%

Technical

RSI(14)57.77

Company Overview

Intellia Therapeutics is a clinical-stage gene editing company developing curative treatments for genetic diseases and cancers. Their main products are in vivo gene editing therapies like NTLA-2001 for transthyretin amyloidosis and NTLA-2002 for hereditary angioedema, alongside engineered cell therapies. The company is a leader in applying CRISPR/Cas9 technology to create novel genomic medicines.

P/B

2.51

Price-to-Book

ROE

-55.4%

Persistent loss

Beta

1.80

High volatility

RSI(14)

57.8

Neutral zone

AI-generated summary. Not investment advice.

Intellia Therapeutics, Inc.

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks